spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  ELIQUIS 

 HSMN NewsFeed - 30 Oct 2024
Laura J. Seplavy, MS, Joins Perosphere as Executive Vice President, Marketing and External Relations
Devices Diagnostics Personnel
 HSMN NewsFeed - 10 Sep 2021
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR(TM) Antithrombotic Removal System During Urgent Cardiothoracic Surgery
Devices Surgery FDA
 HSMN NewsFeed - 12 Aug 2021
Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR(TM) Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery
Devices FDA
 HSMN NewsFeed - 5 Aug 2021
Breckenridge Announces Final Approval of its ANDA for Apixaban Tablets (generic for Eliquis(R))
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 23 Jun 2021
Veralox Therapeutics Appoints Michael Hanna As Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2019
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 Sep 2017
Arvinas Appoints Dr. John Houston as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Feb 2017
Bristol-Myers Squibb Appoints Three New Independent Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Sep 2016
Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Apr 2016
Pfizer Announces Termination of Proposed Combination with Allergan
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Sep 2014
Dimension Therapeutics Names Annalisa Jenkins as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jun 2014
Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Apr 2014
Pfizer Confirms Prior Discussions with AstraZeneca Regarding a Possible Combination and Its Continuing Interest in a Possible Merger Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Mar 2014
Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Feb 2014
In a Subanalysis, Eliquis(R) (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 13 Jan 2014
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis
Biopharmaceuticals
 HSMN NewsFeed - 3 Sep 2013
Subanalysis of Phase III ARISTOTLE Trial of Eliquis(R) (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Dec 2012
Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS(R) (apixaban)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 26 Dec 2012
ELIQUIS(R) (apixaban) Approved In Japan For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 25 Jun 2012
Bristol-Myers Squibb and Pfizer Receive Complete Response Letter from U.S. Food and Drug Administration for ELIQUIS(R) (apixaban)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 20 May 2011
ELIQUIS(R) (apixaban) Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement
Biopharmaceuticals Surgery Orthopaedic
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.